Skip to main content
. 2021 Jan 9;13(1):81. doi: 10.3390/pharmaceutics13010081

Figure 5.

Figure 5

(A,B) Inhibition of OATP1A2-mediated sulforhodamine101 (SR101) uptake by potential antiviral compounds. Uptake of 0.5 μM SR101 was measured in A431-OATP1A2 cells seeded on 96-well plates for 10 min in the presence of increasing concentrations of ivermectin (IVE), chloroquine (CQ), hydroxychloroquine (HCQ), favipiravir(FAV), lopinavir (LOP), ritonavir (RIT), remdesivir (REM), and SEBCD-remdesivir. (C,D) Inhibition of OATP2B1-mediated pyranine uptake by different antiviral compounds. Uptake of 20 μM pyranine was measured in A431-OATP2B1 cells for 15 min in increasing concentrations of the tested compounds. In all cases, averages were obtained based on at least three biological replicates. +/− SD values are shown.